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ABSTRACT
The aim of this work was to develop a micropore-controlled release tablet for theophylline. The tablets were composed of a drug
core surrounded by a microporous film. The major components of coating film included a biocompatible semipermeable polymer,
cellulose acetate, and a water-soluble pore-forming agent, poly(ethylene glycol). The effect of the coating film composition and
the type of excipient incorporated in the drug core on drug release were demonstrated via an in vitro release study. The optimized
formulation was further investigated in vivo of rabbits. The results showed that micropore-controlled release tablets continuously
released drug for 24-36 hours depending on the type of excipient in the drug core and the coating film composition. Incorporation
of lactose in the drug core enhanced drug release from micropore-controlled release tablets. In vivo animal study revealed that the
micropore-controlled release tablets reduced the maximum concentration and prolonged the mean residence time of drug.
Key words: micropore-controlled release tablet, theophylline, cellulose acetate, poly(ethylene glycol), pharmacokinetics

INTRODUCTION
Many studies have examined advantages of sustained
release dosage forms including employing less drug dose,
minimizing side effect, improving therapeutic efficacy,
etc(1). Among sustained release systems, orally controlled
release systems receive the most attraction due to easy
administration and better patient compliance (2). Cellulose
acetate is a well-known semipermeable polymer that
is freely permeable for water but not solutes. Cellulose
acetate has been applied for transdermal delivery system
and as the rate-controlling coating film for osmotic
tablets(3-9). Osmotic systems usually comprise three major
components. The first component is the drug reservoir
which continuously provides the dissolved or suspended
drug. The second component is the semipermeable
coating film which allows water penetration into the
system. The third component is the orifice to control drug
release out of the system. Several variables affect drug
release from osmotic-sustained release systems, including
the drug type, osmotic agent, plasticizer, channeling
agent, composition and the thickness of coating film, and
size of orifice. Proper choices of these variables yield the
desirable drug release profile and therapeutic efficacy.
The new generation of controlled-porosity osmotic
* Author for correspondence. Tel: +886-2-23123456 ext. 88396;
Fax: +886-2-23916126; E-mail: wjlin@ntu.edu.tw

pump has been developed via incorporation of leachable
water-soluble small molecules, such as sodium chloride, potassium chloride, urea, sucrose, etc., into major
components of film(10-13). These pore-forming agents
were leached when contacted with the aqueous medium,
and the pores were created on the films to allow drug
release. The blending of pore-forming agents avoided
using high technique laser to drill the orifice for drug
release and eliminated controlling drug release via
only one orifice. In addition, it was easily fabricated
via a traditional film coating technique instead of high
technique laser (14). Blending a leachable water-soluble
polymer instead of small molecules as a pore-forming
agent was another feasible choice successfully demonstrated by poly(ε-caprolactone)/poly(ethylene glycol)
(PCL/PEG) microporous films (15-18). There were two
major polymers combined in the blended films. PCL
was the component remained in the end-used film, while
PEG acted as a leachable pore-forming agent to produce
porous structure on the film for drug release. Since PCL
and PEG were immiscible polymers, blending both of
them would cause phase separation. The release of drug
from PCL microporous films was completely dominated
by the number of pores and the pore size. However,
the release rate of drug from PCL microporous films
was limited even with high level of the pore-forming
agent. One possible reason was that PCL is a highly
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K30 and K90 were from BASF Chemical Company
(Ludwigshafen, Germany). Theophylline was from SigmaAldrich Chemical Co. Ltd. (St. Louis, MO, USA).

hydrophobic and crystallized polymer that did not allow
water to freely penetrate into the drug core initially.
This resulted in hindering drug dissolution and further
release. In order to improve drug release, the semipermeable polymer might overcome the issue occurred in PCL
microporous films.
The aim of this study was to develop microporecontrolled release tablets for theophylline. The tablets
were composed of a drug core surrounded by the microporous coating film. The major components of the
coating film contained a biocompatible semipermeable
polymer, cellulose acetate, and a water-soluble poreforming agent, poly(ethylene glycol). The effect of the
composition of the coating film and the type of excipient incorporated in the drug core on drug release was
demonstrated via an in vitro release study. Finally, the
optimized formulation was applied for animal study, and
the pharmacokinetic property of theophylline released
from micropore-controlled release tablets was elucidated.

II. Preparation of Coated Tablets
Theophylline without or with 20% of five types
of excipients (e.g., KCl, lactose, starch, PVP K30 and
PVP K90) were weighed in a 3-mm diameter of die and
compressed directly by IR compressor under 2,200 pounds
force for 10 seconds. The theophylline tablets were further
coated. The coating solution was prepared by dissolving
various compositions of cellulose acetate and PEG4000 in
a blended solvent of acetone, ethyl acetate, and ethanol
in the volume ratio of 6 : 6 : 1. Each core tablet with or
without excipient was coated by polymer solution via a
dip-coating method and dried in the oven. Table 1 lists the
compositions of drug core, coating film and the related
symbols for micropore-controlled release tablets.
III. In Vitro Release Study

MATERIALS AND METHODS

The release of theophylline from film-coated tablets
was conducted according to the USP XXXII basket
method. De-ionized water was used as the dissolution medium and maintained at 37 ± 0.5°C. The stirring
speed was set at 50 rpm. Samples (1 mL) were withdrawn
at specific time points, and the same volume of fresh
dissolution medium was replaced. The concentration

I. Materials
Cellulose acetate (CA, M n 30,000) was from Aldrich
Chemical Co. Ltd. (St. Wisconsin, Milwaukee, U.S.A.).
PEG4000 and lactose monohydrate were from Wako Pure
Chemical Co. Ltd. (Osaka, Japan). Polyvinylpyrrolidone

Table 1. The compositions of drug core, coating film and the related symbols for micropore-controlled release tablets
Symbol

Film composition

Tablet

CA/PEG

Theophylline

(%w/w)

(mg)

–

30

–

TH-A0

100 : 0

30

–

TH-A5

95 : 5

30

–

TH-A10

90 : 10

30

–

TH-A20

80 : 20

30

–

TH-A30

70 : 30

30

–

TH-A40

60 : 40

30

–

TH-A50

50 : 50

30

–

TH-Sta-A50

50 : 50

24

Starch

6

TH-KCl-A50

50 : 50

24

KCl

6

TH-Lac-A50

50 : 50

24

Lactose

6

TH-K30-A50

50 : 50

24

Kollindon® 30

6

TH-K90-A50

50 : 50

24

Kollindon® 90

6

–

24

Lactose

6

TH

TH-Lac

Core composition
Excipient
type

weight (mg)
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 Mt 
n

 = Kt
 M  

(1)

where Mt: the amount of drug released at time t
M: total amount of drug in each tablet
K: the release rate constant
n: exponent constant
IV. Morphology of Porous Films
The microporous film was collected at the end of
release study and dried in the oven. They were mounted
on the stage and coated with gold/palladium under an
argon atmosphere. The surface and the cross section
morphology were observed with a scanning electron
microscope (JEOL JSM-6300, Japan).
V. HPLC Condition
Theophylline was assayed with a high performance
liquid chromatography equipped with a reverse-phase
column (Hypersil BDS C18, 250 × 4.6 mm, 5 µm) and a
UV spectrophotometer at 272 nm (Shimadzu SPD-6AV).
The mobile phase of acetonitrile and 0.2 M acetate buffer
solution (pH 4.5) in the volume ratio of 6.5 : 93.5 (%, v/v)
was applied at a flow rate of 1.0 mL/min. The intra- and
inter-day precision and accuracy of the HPLC analytical
method were validated before sample analysis.
VI. Pharmacokinetic Study in Rabbits
Male rabbits were used in this study. They were
obtained from National Taiwan University Experimental
Animal Center. All procedures were examined by the
Ethics Committee on Animal Experiment at National
Taiwan University, and the animal experiment was in
accordance with “Guide for the Care and Use of Laboratory Animals” published by the National Institute of
Health. Each rabbit received intravenous injection of
theophylline solution, orally administered an uncoated
tablet (TH-Lac) and a coated tablet (TH-Lac-A50),
respectively. Blood samples were collected at specific
time points. Plasma concentrations of theophylline were
analyzed with a validated HPLC method. The pharmacokinetic parameters were calculated by using WinNonlin
software (Version 5.2, Pharsight, U.S.A.), and statistically
compared by t-test (α = 0.05). The relationship between the
percentage of drug released in vitro and the percentage of
drug absorbed in vivo was further correlated.

RESULTS AND DISCUSSION
I. Drug Release from Micropore-Controlled Release
Tablets
Figure 1 shows the cumulative release of theophylline from micropore-controlled release tablets coated by
various compositions of CA/PEG. The uncoated theophylline tablet was completely dissolved within 2.5 hours.
However, a sustained-release character was observed
for tablets coated by CA/PEG. Less than 1% of drug was
released from 100% CA-coated tablet (TH-A0) within
36 hours, implying that theophylline cannot directly
diffuse through CA. Incorporation of PEG into CA films
facilitated theophylline release from coated tablets, and
the release rate was prominently enhanced as the level
of PEG increased from 5% to 50% in the coating films.
This result revealed that the release of theophylline from
micropore-controlled release tablets was critically dominated by the extent of micropores after PEG leaching
out. Figure 2 shows the SEM micrographs of 100% CA
film and CA 50%/PEG50% microporous films after PEG
leaching out. The 100% CA film had a smooth surface
without pinholes on it. However, porous structure was
observed on CA-porous films and many micropores
and inter-connected channels were present while PEG
leached out. The CA 50%/PEG50% formed a less-barrier
film with a porous structure and inter-connected channels, which definitely facilitated drug release (Figure
2). The release data up to 60% drug release was further
fitted by equation (1), and the release rate constants K and
n values were obtained in the range of 0.07 ± 0.01 - 7.23 ±
0.29 %h-n and 1.16 ± 0.04 - 0.82 ± 0.02, respectively. The
release rate constants of coated tablets were smaller than
uncoated tablets by 5-500 folds dependent of the level of
PEG blended in the CA films. In other words, increase
in blending level of the pore-forming agent created
more porous morphology of coating films that further
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Cumulative release of theophylline (%)

of theophylline in each sample was determined by UV
spectrophotometer (Hitachi U-2000, Japan) at 272 nm.
In all cases three runs were carried out for each formulation. The accumulative amount of drug released at each
sampling point was corrected with the volume of the
dissolution medium. The release of drug from coated
tablets was further fitted by equation (1)(19).
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Figure 1. The release of theophylline from tablets coated by various
compositions of CA/PEG.
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enhanced drug release from microporous-controlled
release tablets. The possible release mechanism of drug
from coated tablets was further elucidated based on the
n values. The result showed that a zero-order constant
release pattern was switched to an anomalous release
pattern while increasing the level of PEG in the CA films.

This change could be due to faster release of drug from
more porous films resulting in decrease of driving force
across the microporous films. Therefore, the microporecontrolled release tablet could not continuously provide
a constant concentration gradient across the porous film.
Figure 3 shows the cumulative release of theophylline from CA 50%/PEG50% coated tablets composing
different types of excipients in the drug core. The
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Figure 3. The release of theophylline from CA 50% /PEG50% coated
tablets in the presence of different excipients in the drug core.

Pre-microporous film

Drug core tablet

Water

Water

PEG leach out

(b)

Micropore-controlled release tablet

Microporous film

(c)
Figure 2. The SEM micrographs of (a) CA100% (surface morphology),
(b) CA 50%/PEG50% microporous film (surface morphology), and (c)
CA50%/PEG50% microporous film (cross section morphology).

Drug permeate
through the pores

Micropore

H2O in
Interconnected channel

Figure 4. The proposed model for micropore-controlled release
tablets.
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Table 2. The pharmacokinetic parameters of theophylline after intravenous injection of solution or oral administrations of uncoated tablets
(TH-Lac) and coated tablets (TH-Lac-A50) (n = 5)
IV-TH

Oral TH-Lac

Oral TH-Lac-A50

Cmax (µg/mL)

21.15 ± 1.99

14.79 ± 1.36

8.93 ± 1.91

Tmax (hr)

0.25 ± 0.00

3.40 ± 0.55

13.60 ± 1.67

AUC∞ (µg•hr/mL)

116.54 ± 25.88

146.89 ± 19.42

141.33 ± 27.97

MRT (hr)

7.70 ± 1.16

11.25 ± 1.47

15.65 ± 1.72

dissolution of drug from TH-Lac uncoated tablet was
completed within 2.5 hours which was much shorter
than the coated tablets. The result showed that the drug
continuously released from the micropore-controlled
release tablets for 24 - 36 hours dependent of the type
of excipient, which was in the order of TH-Lac-A 50 >
TH-K90-A 50 - TH-K30-A 50 > TH-A 50 > TH-KCl-A 50 TH-Sta-A 50. Lactose enhanced theophylline solubility
and increased the osmotic pressure of the drug core
which made a positive contribution for drug release.
Although potassium chloride produced the highest
osmotic pressure in the drug core, the salting-out effect
and quick release of KCl from the drug core resulted in
slight reduction of drug release. The similar result was
also observed with starch as the excipient. Although
starch was able to absorb water and allowed tablet disintegration, its low water solubility hindered drug release
from micropores. The release data up to 60% drug
released were further fitted by equation (1), and the n
values were in the range of 0.8 - 0.9. The model for drug
release from micropore-controlled release tablets was
further proposed in Figure 4. CA was a semipermeable
membrane which allowed water to penetrate into the drug
core at beginning. Simultaneously, the pore-forming
agent PEG started to dissolve and leach out of the coating
film after contact with the medium, and the micropores
were formed in the CA films. These micropores not only
enhanced water diffusion into drug core to dissolve drug,
but also provided the route for drug release from the
micropore-controlled release tablets.
II. Pharmacokinetic Property of Micropore-controlled
Release Tablet
The TH-Lac-A 50 coated tablet was further applied
to in vivo animal study, where the lactose was incorporated in the drug core and the composition of coating
film was CA 50%/PEG50% . Figure 5 shows the plasma
drug concentration after intravenous injection of
theophylline solution, oral administrations of uncoated
(TH-Lac) and coated (TH-Lac-A 50) theophylline tablets
respectively. The related pharmacokinetic parameters are listed in Table 2. The highest drug concentration appeared at the beginning followed by quick

Theophylline plasma concentration (µg/mL)

Parameter
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Figure 5. Plasma drug concentrations after intravenous injection
of theophylline solution or oral administration of uncoated tablets
(TH-Lac) and coated tablets (TH-Lac-A50).

reduction within 24 hours after intravenous injection.
Oral administration of uncoated tablet (TH-Lac) reduced
the maximum concentration (Cmax) from 21.15 ± 1.99 to
14.79 ± 1.36 µg/mL. Oral administration of coated tablet
(TH-Lac-A 50) further reduced the maximum concentration to 8.93 ± 1.91 µg/mL, and the time to reach Cmax was
postponed from 3.40 ± 0.55 to 13.60 ± 1.67 hr. The mean
residence time (MRT) was prolonged from 11.25 ± 1.47
to 15.65 ± 1.72 hr after oral administration of coated
tablets, but there was no significant difference in AUC 
between coated and uncoated tablets. Obviously more
lasting and less fluctuation of plasma drug concentrations
were observed after administration of coated TH-LacA 50 tablets. The correlation between the percentage
of drug absorbed in vivo and the percentage of drug
released in vitro is shown in Figure 6. Both showed a
good in vitro-in vivo correlation with the equation y =
1.068x - 6.795 with a correlation coefficient of 0.989.

CONCLUSIONS
The micropore-controlled release tablet continuously released drug for 24-36 hours dependent of the type
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Figure 6. In vitro-in vivo correlation of theophylline released from
micropore-controlled release tablets.

of excipient in the drug core and the composition of the
coating film. Incorporation of lactose in the drug core
enhanced drug release from micropore-controlled release
tablets. The porous structure built on the CA film dominated theophylline release from the micropore-controlled
release tablets. The importance of micropores on the
semipermeable CA films not only enhanced water diffusion into drug core to dissolve drug, but also provided
the route for drug release from the micropore-controlled
release tablets. The animal study showed that TH-LacA 50 micropore-controlled release tablets reduced the
maximum concentration, delayed the time to reach Cmax
and prolonged MRT in vivo.
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